Ibandronsäure Genericon (Ibandronic Acid Monosodium Salt, Monohydrate)

Ibandronic acid binds to hydroxyapatite in bone and is taken up by osteoclasts during bone resorption. Inside the cell it inhibits farnesyl pyrophosphate synthase, disrupting the mevalonate pathway, which leads to osteoclast apoptosis and a consequent reduction in bone turnover.

The specific dose and infusion schedule are determined by the prescribing clinician based on the patient’s condition, renal function, and other clinical factors. Healthcare providers follow approved guidelines and adjust the regimen as needed for safety and efficacy.

Safety data for ibandronic acid during pregnancy and lactation are limited. It should only be used when clearly necessary, and the potential benefits must outweigh any unknown risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

Ibandronic acid is similar to other intravenous bisphosphonates such as zoledronic acid, but it is typically administered less frequently (e.g., every 3 months) and may have a slightly different safety profile, especially regarding acute phase reactions. Choice of agent depends on patient tolerance, renal function, and physician preference.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. It should be kept in its original packaging until use to maintain stability and sterility.

Ibandronsäure Genericon is given as an intravenous infusion. The solution is administered over a short period, typically 15–30 minutes, under medical supervision. Patients are monitored for acute reactions during and after the infusion.

Serious adverse events include osteonecrosis of the jaw, atypical femoral fractures, severe renal impairment, and profound hypocalcemia that can lead to cardiac arrhythmias. Prompt recognition and management of these conditions are essential, and patients should be educated about warning signs.

Contraindications include patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to ibandronic acid or any formulation components, and those with existing hypocalcemia that has not been corrected. Caution is also advised for individuals with active dental problems or recent oral surgery.